AP NEWS
ADVERTISEMENT
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Novadiscovery appoints Grégoire Boutonnet as Chief Operating Officer

July 22, 2021 GMT

Novadiscovery appoints Grégoire Boutonnet as Chief Operating Officer

A ppointment of Grégoire support s NOVA’s continued international expansion

Lyon, France – 22 July 2021: Novadiscovery (NOVA), a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces the appointment of Grégoire Boutonnet as Chief Operating Officer, effective immediately. In his new role, Grégoire will ensure alignment between NOVA’s business strategy, operations and growth objectives, as well as leading the Modelling and Simulation (M&S) team as NOVA embarks on its next phase of expansion.

Grégoire brings more than 20 years of technological innovation, strategy and digital entrepreneurship experience to the team. He started his career as the founder and CEO of Andrexen, an innovative Unified Communication Cloud Platform. Grégoire then joined telecoms service provider Cirpack, following its acquisition of Andrexen, as Chief Marketing and Product Officer. He most recently held the position of Chief Strategy Officer at Experty.io, a blockchain-based knowledge sharing platform.

ADVERTISEMENT

Grégoire holds a Masters’ degree in Fundamental Physics from Pierre and Marie Curie University.

François-Henri Boissel, CEO of NOVA, commented: “ Grégoireis anindustry trail blazer withovertwo decadesof experiencein innovation, product strategy and digital entrepreneurship. Hejoins us at a pivotal time asourJinkō®platform goes from strength to strengthas we expand ourportfolio of partnerships.Grégoire’s strategic and operational expertisewill bea vital part ofour future success inacceleratingandde-riskingclinical trials.As we expand our offering into the US and beyond, NOVAaims to become the go-to partner for pharma and biotech companies for in silico clinical trial support.I am delighted to welcome Grégoire to theNovadiscoveryteam and look forward to working closely with him.

ADVERTISEMENT

Grégoire Boutonnet, Chief Operating Officer of NOVA, said: “ I amthrilledto be joiningtheNOVAteamat this excitingperiod ofgrowthas welaunch theJinkōplatform towards wideradoption in the clinical trial development space.Ilookforwardtoworkingalongside such anambitiousteam whoare passionate about using cutting-edge technologytosolvethe health issues of the futureand meet the needs ofpharma and biotechcompaniesacross the globe.”

Ends

For more information, please contact:

Novadiscovery
François-Henri Boissel, Chief Executive Officer
Email: contact@novadiscovery.com

Consilium Strategic Communications
Sukaina Virji, Carina Jurs, Kris Lam
Email: novadiscovery@consilium-comms.com

About Novadiscovery

Novadiscovery is a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development. The Company aims to improve R&D productivity and maximize patient outcomes by predicting the clinical benefit of a potential new drug candidate through computer simulation, ahead of human trials.

Novadiscovery’s innovative approach leverages disease modeling and simulation expertise accumulated over the past decade and combines mathematical models of diseases and potential new treatments with virtual patients in its integrated clinical trial simulation platform, Jinkō®.

Novadiscovery is headquartered in Lyon, France and has a team of around 30 scientists, engineers & clinicians who work at the interface of biology, pharmacology, mathematics & computer science.

For more information, please visit https://www.novadiscovery.com and follow us on Twitter @novadiscovery and linkedin.com/company/novadiscovery